Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...

EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.